期刊文献+

子宫内膜腺癌组织中尿激酶型纤溶酶原激活系统的表达及其临床意义

Clinical significance of the expression of urokinase type plasminogen activator system in endometrial carcinoma
下载PDF
导出
摘要 目的:研究尿激酶型纤溶酶原激活系统在子宫内膜腺癌的发生、发展及浸润转移中的规律及其对临床的指导意义。方法:应用免疫组织化学方法测定24例正常子宫内膜、30例子宫内膜增生过长及62例子宫内膜腺癌组中uPA、uPAR、PAI-1的表达,并分析与良恶性、临床分期、组织学分级、基层浸润深度及淋巴结转移的关系。结果:uPA、uPAR、PAI-1在子宫内膜腺癌组中的表达较正常子宫内膜组和子宫内膜增生过长组中的表达显著升高(P均<0.05),而正常子宫内膜组和子宫内膜增生过长组中的表达无显著性差异(P>0.05)。uPA、uPAR、PAI-1的高表达与肿瘤分化、临床分期、肌层浸润深度和淋巴结转移有关(P<0.05)。结论:uPA、uPAR、PAI-1的表达与子宫内膜腺癌的发生、发展及浸润转移密切相关,可作为判断预后的重要指标。 Objective:To investigate the clinical significance of the expression of urokinase type plasminogen activator system in oceurance,progression and invasion endometrial carcinoma. Methods:Uslng immunohistoehemistry, the expression of uPA, uPAR and PAI - 1 in 24 cases of normal endometrium ,30 cases of hyperplasia of endometrium and 62 cases of endometrial carcinoma was examined, and the relation with benign and malignant diseases, clinical stages, histological grade, muscle invasion and lymphnode metastasis was observed, Results : In endometrial carcinoma tissues, the positive rates of uPA, uPAR and PAI- 1 were significantly higher than that of normal endometrium and hyperplasia of endometrium tissues( P 〈 0.05 ). The high expression of uPA, uPAR and PAI- 1 was correlated with histological grade, clinical stage, muscle invasion and lymphnode metastasis ( P 〈 0.05 ). Conclusion: The expression of uPA, uPAR and PAI- 1 is positively correlated with the occurrence, progression, invasion and metastasis of endometrial carcinoma. They are useful prognostic makers for biologically aggressive forms of endometrial carcinoma.
出处 《现代肿瘤医学》 CAS 2009年第11期2195-2197,共3页 Journal of Modern Oncology
关键词 UPA UPAR PAI-1 子宫内膜腺癌 uPA uPAR PAI- 1 endometrial carcinoma
  • 相关文献

参考文献5

  • 1Czekay RP,Aertgeerts K, Curriden SA, et al. Plasminogen activator inhibitor - 1 detaches cells from extracellular matrices by inactivating integrins[ J]. Cell Biol,2003,160(5) :781 -791.
  • 2Tecimer C ,Doefing DL,Goldsmith LJ,et al. Clinical relevance of urokinase- type plasminogen activator,its receptor, and its inhibitor type 1 in endometrial cancer[ J]. Gynecol Oncol,2001,80( 1 ) :48 -55.
  • 3Gerstein ES, Gristsaenko EV, Shcherbakov ME, et al. Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia[ J ]. Vopr Onkol, 2003,49 ( 6 ) : 725 - 729.
  • 4Memarzadeh S, Kozak KR, Chang L, et al. Urokinase plasminogen activator receptor:Prognostic biomarker for endometrial cancer [ J ]. Proc Natl Acad Sci USA,2002,99(16) :1047 -1052.
  • 5Foca C, Mosses EK, Quinn MA, Rice GE. Differential mRNA expression of urokinase - type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type - 2 in normal human endometria and endometrial carcinomas [ J ]. Gynecol Oncol,2000,79 ( 2 ) : 244 - 250.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部